Elephas Biosciences announces exclusive commercial partnership in India with Neuberg Diagnostics

Elephas Biosciences Corporation, a US-based company that has developed an innovative live tissue platform for immunotherapy response prediction, has announced an exclusive partnership with Chennai-based Neuberg Diagnostics, one of India's leading pathology and molecular diagnostics groups. Under the agreement, Neuberg will become Elephas' commercial partner in India, marking a significant step in Elephas' global commercialisation strategy.

Elephas continues to pursue strategic partnerships with international organisations that share its mission of improving outcomes for patients undergoing immunotherapy. Together with Elephas, Neuberg will bring the elive™ platform into its own laboratory infrastructure, with the goal of launching its own clinical test in India by the end of 2026. 

The partnership combines Neuberg's established oncology diagnostics expertise with Elephas' functional research platform. Pairing these complementary technologies provides oncologists with a more comprehensive view of cancer by integrating molecular profiling with live tumor functional testing.

Alongside the commercial agreement, Neuberg will serve as Elephas' research partner in India, processing tumour biopsy samples on the elive platform at its flagship laboratory in Ahmedabad. This research is expected to generate local evidence supporting the platform's performance as it moves toward broader adoption.